Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Lexicon Pharmaceuticals, Inc. (LXRX)

2.145   -0.015 (-0.69%) 12-06 10:08
Open: 2.18 Pre. Close: 2.16
High: 2.19 Low: 2.14
Volume: 22,069 Market Cap: 405(M)

Technical analysis

as of: 2022-12-06 9:49:24 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.64     One year: 2.87
Support: Support1: 1.95    Support2: 1.62
Resistance: Resistance1: 2.26    Resistance2: 2.46
Pivot: 2.17
Moving Average: MA(5): 2.17     MA(20): 2.18
MA(100): 2.49     MA(250): 2.5
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 43.8     %D(3): 41.9
RSI: RSI(14): 50.3
52-week: High: 4.71  Low: 1.3
Average Vol(K): 3-Month: 493 (K)  10-Days: 281 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ LXRX ] has closed below upper band by 47.7%. Bollinger Bands are 54.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.24 - 2.25 2.25 - 2.26
Low: 2.08 - 2.09 2.09 - 2.1
Close: 2.14 - 2.16 2.16 - 2.18

Company Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Headline News

Mon, 28 Nov 2022
2022-11-28 | NDAQ:LXRX | Press Release | Lexicon Pharmaceuticals Inc. - Stockhouse

Tue, 15 Nov 2022
Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study - Yahoo Finance

Wed, 09 Nov 2022
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript - Seeking Alpha

Sun, 06 Nov 2022
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure - Yahoo Finance

Sun, 06 Nov 2022
Lexicon Pharmaceuticals (LXRX) will report earnings on Wednesday. - Best Stocks

Tue, 11 Oct 2022
Private equity firms among Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest stockholders and were hit after last week's 12% price drop - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 189 (M)
% Held by Insiders 8.062e+007 (%)
% Held by Institutions 1 (%)
Shares Short 4,480 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -9.538e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -76
Return on Assets (ttm) 649.5
Return on Equity (ttm) -33
Qtrly Rev. Growth 125000
Gross Profit (p.s.) 51.17
Sales Per Share -50.87
EBITDA (p.s.) -4.02574e+007
Qtrly Earnings Growth -0.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -90 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 3.91

Stock Dividends

Dividend 0
Forward Dividend 4.26e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.